RIGEL PHARMACEUTICALS INC

Rigel Pharmaceuticals is a biotechnology company focused on discovering and developing therapies for hematologic disorders and cancer. The company operates primarily through commercialized products in oncology and immunology. Tavalisse, an oral spleen tyrosine kinase inhibitor, treats chronic immune thrombocytopenia in adults. Rezlidhia addresses relapsed or refractory acute myeloid leukemia with IDH1 mutations, while GAVRETO, a kinase inhibitor, is indicated for RET fusion-positive non-small cell lung cancer and thyroid cancer in adults and pediatric patients aged twelve and older.

The company maintains an active clinical development pipeline, with R289, an IRAK1/4 inhibitor, in development for hematology-oncology, autoimmune, and inflammatory conditions, including lower-risk myelodysplastic syndrome. Rigel has established strategic collaborations with major pharmaceutical companies including Eli Lilly and Daiichi Sankyo, and maintains a research partnership with The University of Texas MD Anderson Cancer Center for combination therapy development in high-grade glioma.

Based in South San Francisco, California, Rigel operates with approximately 162 full-time employees. The company was incorporated in Delaware in 1996 and is listed on the Nasdaq.